Abstract CD95 (APO-1/Fas) is a prototype death receptor characterized by the presence of
an 80 amino acid death domain in its cytoplasmic tail. This domain is essential for the …

In 1989 we published a paper describing the discovery of an apoptosis-inducing receptor
[1]. We named this receptor APO-1, anticipating that it might be the first of a series of …

We have identified two cell types, each using almost exclusively one of two different CD95
(APO‐1/Fas) signaling pathways. In type I cells, caspase‐8 was activated within seconds …

Apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL/APO-2L) has been shown to exert important functions during various immunological …

Activation of the caspase cascade is a pivotal step in apoptosis and can occur via death
adaptor‐mediated homo‐oligomerization of initiator procaspases. Here we show that c‐FLIP …

Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF
family of cytokines that promotes apoptosis. TRAIL induces apoptosis via death receptors …

CD95 (APO-1/Fas) has become the prototype of a death domain containing receptor and is
the best studied member of the death receptors that activate the extrinsic apoptosis pathway …

This review covers recent advances of CD95 signaling. It focuses on CD95-interacting
molecules, formation of the death inducing signaling complex and the role of caspases …

The concept for cellular immunotherapy of solid tumors relies heavily on the capacity of
class I MHC-restricted cytotoxic T lymphocytes (CTLs) to eliminate tumor cells. However …

The involvement of the death adaptor protein FADD and the apoptosis‐initiating caspase‐8
in CD95 and TRAIL death signalling has recently been demonstrated by the analysis of the …